Loading…
CollPlant Biotechnologies Ltd. is projected to decline to $0.3299 by 2027, a -10% move from its current price of $0.368. CLGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.347 | $0.368 | $0.3904 | +0.01% |
| Jul 14 | $0.3387 | $0.3681 | $0.40 | +0.03% |
| Jul 15 | $0.3325 | $0.3681 | $0.4076 | +0.04% |
| Jul 16 | $0.3273 | $0.3682 | $0.4142 | +0.05% |
| Jul 17 | $0.3229 | $0.3682 | $0.42 | +0.07% |
| Jul 18 | $0.3189 | $0.3683 | $0.4254 | +0.08% |
| Jul 19 | $0.3152 | $0.3683 | $0.4304 | +0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3152 | $0.3683 | $0.4304 | +0.09% |
| Week 2 | $0.2958 | $0.3687 | $0.4595 | +0.19% |
| Week 3 | $0.2818 | $0.369 | $0.4832 | +0.28% |
| Week 4 | $0.2706 | $0.3694 | $0.5043 | +0.37% |
| Week 5 | $0.261 | $0.3697 | $0.5236 | +0.46% |
| Week 6 | $0.2527 | $0.3701 | $0.5418 | +0.56% |
| Week 7 | $0.2454 | $0.3704 | $0.5591 | +0.65% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CollPlant Biotechnologies Ltd. is a healthcare company focused on regenerative and aesthetic medicine, with emphasis on three-dimensional (3D) bioprinting of tissues and organs and medical aesthetics across the United States, Canada, Israel, Europe, and internationally.
Its products are based on recombinant human collagen (rhCollagen) produced with its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds.
It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd.
and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
CollPlant Biotechnologies Ltd. (CLGN) operates in the healthcare sector, focusing on regenerative and aesthetic medicine.
A major floor 23.6% below — a decisive break under it would weaken the trend.
The nearest floor, 9.5% below — buyers have tended to step in here.
The nearest ceiling, 16.3% above — a clean break opens room to run.
A major ceiling 103.8% above — clearing it would confirm fresh momentum.
Key CLGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.3766 | Sell | $0.366 | Buy |
| MA 10 | $0.3612 | Buy | $0.3624 | Buy |
| MA 20 | $0.3497 | Buy | $0.3621 | Buy |
| MA 50 | $0.3823 | Sell | $0.4029 | Sell |
| MA 100 | $0.4542 | Sell | $0.5935 | Sell |
| MA 200 | $1.18 | Sell | $1.07 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.40 | Neutral |
| Stoch RSI (14) | 54.81 | Neutral |
| CCI (20) | 79.21 | Neutral |
| Williams %R (14) | -63.16 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 4.55 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 36.84 | Neutral |
| TRIX (15) | -0.36 | Sell |
| Awesome (5,34) | 0.01 | Buy |
| Ultimate (7,14,28) | 53.82 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 0.37 | Sell |
| ADX (14) | 16.47 | Neutral |
| ATR (14) | 0.02 | Info |
Current price: $0.36; Market cap: $5.19M; Rank: 5324. The 30-day technical picture shows NEUTRAL sentiment with RSI14 at 50. The 50-day SMA is $0.3848 and the 200-day SMA is $1.21. Support is at $0.333 and resistance at $0.428. The 30-day price range runs from $0.236 to $0.549.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.293 | $0.368 | $0.5204 | 0% | Neutral | |
| $0.2393 | $0.3299 | $0.4915 | -10% | Neutral | |
| $0.2377 | $0.3482 | $0.5529 | -5% | Neutral | |
| $0.2165 | $0.3341 | $0.557 | -9% | Neutral | |
| $0.2713 | $0.4388 | $0.7615 | +19% | Neutral | |
| $0.3063 | $0.5178 | $0.9303 | +41% | Bullish | |
| $0.2868 | $0.5057 | $0.9368 | +37% | Bullish | |
| $0.2873 | $0.5275 | $1.00 | +43% | Bullish | |
| $0.2503 | $0.4782 | $0.9335 | +30% | Bullish | |
| $0.2174 | $0.4317 | $0.8623 | +17% | Neutral | |
| $0.3125 | $0.6944 | $1.52 | +89% | Bullish | |
| $0.4223 | $0.9385 | $2.16 | +155% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.293 | $0.368 | $0.4663 | +0.00% |
| August 2026 | $0.3227 | $0.3908 | $0.493 | +6.20% |
| September 2026 | $0.3032 | $0.3725 | $0.4797 | -4.70% |
| October 2026 | $0.3017 | $0.3751 | $0.4916 | +0.71% |
| November 2026 | $0.3163 | $0.3975 | $0.5285 | +5.97% |
| December 2026 | $0.3045 | $0.3863 | $0.5204 | -2.81% |
Click any year to see its month-by-month CLGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CLGN is projected to trade between $0.293 and $0.5204, averaging $0.368 — a potential gain of 0% from today's $0.368. A consolidation phase looks the most probable path here.
CollPlant Biotechnologies Ltd.'s 2027 outlook centres on $0.3299, within a $0.2393 to $0.4915 range. That is -10% versus the projected 2026 average. That marks a -10% change versus current levels. Price action looks broadly range-bound.
By 2028, CLGN could reach as high as $0.5529, with a base case around $0.3482 and support toward $0.2377 — roughly -5% from $0.368. A consolidation phase looks the most probable path here.
Expect CLGN to range from $0.2165 to $0.557 through 2029. The $0.3341 average target implies a -9% move from current prices. That is -4% versus the projected 2028 average. Price action looks broadly range-bound.
The CLGN price prediction for 2030 points to an average of $0.4388 (low $0.2713, high $0.7615) — a potential gain of +19% on today's $0.368. A consolidation phase looks the most probable path here.
In 2031, CLGN is projected to trade between $0.3063 and $0.9303, averaging $0.5178 — a potential gain of +41% from today's $0.368. That is up +18% on the projected 2030 average. Momentum favours further upside here.
CollPlant Biotechnologies Ltd.'s 2032 outlook centres on $0.5057, within a $0.2868 to $0.9368 range. That is -2% versus the projected 2031 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CLGN could reach as high as $1.00, with a base case around $0.5275 and support toward $0.2873 — roughly +43% from $0.368. Momentum favours further upside here.
Expect CLGN to range from $0.2503 to $0.9335 through 2034. The $0.4782 average target implies a +30% move from current prices. That is -9% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The CLGN price prediction for 2035 points to an average of $0.4317 (low $0.2174, high $0.8623) — a potential gain of +17% on today's $0.368. Price action looks broadly range-bound.
In 2040, CLGN is projected to trade between $0.3125 and $1.52, averaging $0.6944 — a potential gain of +89% from today's $0.368. That is up +61% on the projected 2035 average. Buyers look set to stay in control over this stretch.
CollPlant Biotechnologies Ltd.'s 2050 outlook centres on $0.9385, within a $0.4223 to $2.16 range. That is up +35% on the projected 2040 average. That marks a +155% change versus current levels. Momentum favours further upside here.
Investing $1,000 in CLGN today (≈ 2,717.391304 CLGN) could be worth
$2,550.28
+$1,550.28 (+155%) by 2050 · US Dollar
Based on the average projected CLGN price of $0.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLGNwould be worth at today's price.
$1,000 invested in CLGN on Jul 10, 2025 (≈ 709.219875 CLGN) would be worth
$260.99
-$739.01 (-73.9%) today · 0.26× · US Dollar
Based on a CLGN entry price of $1.41 vs. today's $0.368.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.34 | $1,082.35 | +8.2% |
| 1 month ago | $0.363 | $1,013.77 | +1.4% |
| 3 months ago | $0.382 | $963.35 | -3.7% |
| 6 months ago | $1.51 | $243.71 | -75.6% |
| 1 year ago | $1.41 | $260.99 | -73.9% |
| All time (5.0y) ago | $19.06 | $19.31 | -98.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLGN forecast.
Our base-case forecast reaches $0.74 around 2050.
Implied market cap at $0.74: $13.99M
Forecasts show a path from near-term neutral to longer-term upside. For 2026 the avg price is $0.36 with ROI 0 and neutral sentiment. By 2030 the avg rises to $0.4136 with ROI 14.9 and neutral sentiment; the 2030 min/max are $0.2556 and $0.718 respectively.
From 2031 to 2034 the forecast is bullish, with avg prices between $0.4789 and $0.4949 and ROIs of 37.5, 33, 40.4, and 27 respectively. The 2040 forecast shows an avg of $0.6587 with ROI 83 and a max of $1.45, while 2050 projects an avg of $0.8598 with ROI 138.8 and a max of $1.98. These are estimates, not guarantees.
Risks include mixed near-term performance before longer-term upside is realized, and outcomes depend on market conditions and execution of business plans.
Tap a question to reveal the answer.
Avg price is $0.4136; min $0.2556; max $0.718; ROI 14.9; sentiment NEUTRAL.
The 2040 forecast max is $1.45, which would exceed $1; avg is $0.6587 and ROI 83.
Min $0.293; avg $0.36; max $0.5037; ROI 0; sentiment NEUTRAL.
Forecast shows mixed near term with negative ROIs in 2027–2029 (e.g., 2027 ROI -11.2, 2028 ROI -5.6, 2029 ROI -12.4), but longer term supports bullish potential by 2030 onward (e.g., 2030 ROI 14.9; 2040 ROI 83; 2050 ROI 138.8). These are estimates, not guarantees.
Avg price $0.8598; min $0.3869; max $1.98; ROI 138.8; sentiment BULLISH.
CollPlant Biotechnologies Ltd. Community Discussion
0Share your CollPlant Biotechnologies Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.